Global Healthcare Analyst

Tina Banerjee

Equity Bottom-Up

<ul>
<li>
<a href="https://www.smartkarma.com/entities/csl-ltd" target="_blank" data-smartkarma-citation="entities:917:1" rel="noopener">CSL Ltd (CSL AU)</a> has reported strong financial performance in H1FY24, with revenue and net profit growing 11% and 20%, YoY, respectively. Growth was mainly driven by immunoglobulins franchise.</li>
<li>CSL reaffirmed FY24 guidance. Revenue growth is anticipated to be 9–11% YoY at constant currency. NPATA is anticipated to be $2.9–3.0B at constant currency, up 13–17% YoY.</li>
<li>The company is confident to deliver double-digit earnings growth over the medium term, citing strong demand for immunoglobulins and successful initiatives in plasma collections that are enhancing efficiencies.</li>
</ul>



CSL Ltd (CSL AU) has reported strong financial performance in H1FY24, with revenue and net profit growing 11% and 20%, YoY, respectively. Growth was mainly driven by immunoglobulins franchise.
CSL reaffirmed FY24 guidance. Revenue growth is anticipated to be 9–11% YoY at constant currency. NPATA is anticipated to be $2.9–3.0B at constant currency, up 13–17% YoY.
The company is confident to deliver double-digit earnings growth over the medium term, citing strong demand for immunoglobulins and successful initiatives in plasma collections that are enhancing efficiencies.


CSL Ltd (CSL AU): Double-Digit Sales and Profit Growth in H1FY24 Led by Immunoglobulin Franchise

Asia Pac ECM and Index Rebal, Shenton Research

Ke Yan, CFA, FRM

Asia Pac ECM and Index Rebal

Asia Pac IPO & Placement Research, China Biotech

DZT Research

DZT Research is an independent Asia Pacific equity specialist. Our quantitative research covers index rebalancing flows, alongside exchange data analytics accross Asia Pacific. On the equity capital markets side, we focus on Asia Pacific ECM, especially biotech and TMT. Our lead analyst is frequently cited by international media.

Quantitative Analysis

<ul>
<li>We analyzed the changes in short interest of ASX Stocks as of Feb 2nd (reported today) which has an aggregated short interest worth USD18.3bn.</li>
<li>We tabulate league table for top short by value and short as multiple of ADT, as well as weekly increases &amp; decreases in short value, short as multiple of ADT.</li>
<li>We highlight short interest changes in Fortescue, Rio Tinto, Wisetech Global.</li>
</ul>


We analyzed the changes in short interest of ASX Stocks as of Feb 2nd (reported today) which has an aggregated short interest worth USD18.3bn.
We tabulate league table for top short by value and short as multiple of ADT, as well as weekly increases &amp; decreases in short value, short as multiple of ADT.
We highlight short interest changes in Fortescue, Rio Tinto, Wisetech Global.


ASX Short Interest Weekly (Feb 2nd): Fortescue, Rio Tinto, Wisetech Global

<ul>
<li>We analyzed the changes in short interest of ASX Stocks as of Jan 26th (reported today) which has an aggregated short interest worth USD18.1bn.</li>
<li>We tabulate league table for top short by value and short as multiple of ADT, as well as weekly increases &amp; decreases in short value, short as multiple of ADT.</li>
<li>We highlight short interest changes in ANZ, CSL, Domino'S Pizza.</li>
</ul>


We analyzed the changes in short interest of ASX Stocks as of Jan 26th (reported today) which has an aggregated short interest worth USD18.1bn.
We tabulate league table for top short by value and short as multiple of ADT, as well as weekly increases &amp; decreases in short value, short as multiple of ADT.
We highlight short interest changes in ANZ, CSL, Domino'S Pizza.


ASX Short Interest Weekly (Jan 26th): ANZ, CSL, Domino'S Pizza

<ul>
<li>We analyzed the changes in short interest of ASX Stocks as of Jan 12th (reported today) which has an aggregated short interest worth USD18.6bn.</li>
<li>We tabulate league table for top short by value and short as multiple of ADT, as well as weekly increases &amp; decreases in short value, short as multiple of ADT.</li>
<li>We highlight short interest changes in Aristocrat Leisu, IDP Education, Fortescue, South32, Star Entertainme, BHP, CSL, Wesfarmers.</li>
</ul>


We analyzed the changes in short interest of ASX Stocks as of Jan 12th (reported today) which has an aggregated short interest worth USD18.6bn.
We tabulate league table for top short by value and short as multiple of ADT, as well as weekly increases &amp; decreases in short value, short as multiple of ADT.
We highlight short interest changes in Aristocrat Leisu, IDP Education, Fortescue, South32, Star Entertainme, BHP, CSL, Wesfarmers.


ASX Short Interest Weekly (Jan 12th): Aristocrat Leisu, IDP Education, Fortescue, South32, BHP, CSL

<ul>
<li>We analyzed the changes in short interest of ASX Stocks as of Dec 8th (reported today) which has an aggregated short interest worth USD18.9bn.</li>
<li>We tabulate league table for top short by value and short as multiple of ADT, as well as weekly increases &amp; decreases in short value, short as multiple of ADT.</li>
<li>We highlight short interest changes in Wisetech Global, Mineral Resource, Liontown, ANZ, CSL, Macquarie, Car.</li>
</ul>


We analyzed the changes in short interest of ASX Stocks as of Dec 8th (reported today) which has an aggregated short interest worth USD18.9bn.
We tabulate league table for top short by value and short as multiple of ADT, as well as weekly increases &amp; decreases in short value, short as multiple of ADT.
We highlight short interest changes in Wisetech Global, Mineral Resource, Liontown, ANZ, CSL, Macquarie, Car.


ASX Short Interest Weekly (Dec 8th): Wisetech Global, Mineral Resource, Liontown, ANZ, CSL

United States

CSL Limited develops, manufactures, and markets human pharmaceutical and diagnostic products derived from human plasma. The Company provides products include pediatric and adult vaccines, infection, pain medicine, skin disorder remedies, antivenoms, anticoagulants, and immunoglobulins.

Price Gauge
52-week Range	0.00 - 0.00
Market Cap (USDm)	0.00
P/E	0.00
Dividend (Yield)	0.00

CSL (CSL AT)

CSL Ltd (CSL AU): Double-Digit Sales and Profit Growth in H1FY24 Led by Immunoglobulin Franchise

In H1FY24, CSL reported 23% YoY growth in revenue from Immunoglobulin. The company has reaffirmed FY24 guidance. FY24 revenue and NPATA are...

Tina Banerjee

ASX Short Interest Weekly (Feb 2nd): Fortescue, Rio Tinto, Wisetech Global

We analyzed ASX short interest report for the past week and highlight short interest changes in Fortescue, Rio Tinto, Wisetech Global.

Ke Yan, CFA, FRM

ASX Short Interest Weekly (Jan 26th): ANZ, CSL, Domino'S Pizza

We analyzed ASX short interest report for the past week and highlight short interest changes in ANZ, CSL, Domino'S Pizza.

Ke Yan, CFA, FRM

ASX Short Interest Weekly (Jan 12th): Aristocrat Leisu, IDP Education, Fortescue, South32, BHP, CSL

We analyzed ASX short interest report for the past week and highlight short interest changes in Aristocrat Leisu, IDP Education, Fortescue,...

Ke Yan, CFA, FRM

ASX Short Interest Weekly (Dec 8th): Wisetech Global, Mineral Resource, Liontown, ANZ, CSL

We analyzed ASX short interest report for the past week and highlight short interest changes in Wisetech Global, Mineral Resource, Liontown, ANZ,...

Ke Yan, CFA, FRM

Price Gauge

52-week Range

Market Cap (USDm)

P/E

Dividend (Yield)